Awakn Life Sciences (TSE:AWKN) has released an update.
Awakn Life Sciences Corp. has commenced a groundbreaking Phase 3 clinical trial, screening the first patient for a novel treatment of severe Alcohol Use Disorder (AUD) using the drug AWKN-001, which combines ketamine with psycho-social support. The ‘MORE-KARE’ study, the largest of its kind, is co-funded by UK’s health agencies and aims to significantly reduce heavy drinking days over a six-month period. The trial, which might revolutionize treatment for severe AUD, is being conducted at eight NHS sites in the UK.
For further insights into TSE:AWKN stock, check out TipRanks’ Stock Analysis page.
